Integrated Filing — IndAS

General information about company
Scrip Code	524715
NSE Symbol	SUNPHARMA
MSEI Symbol	NOTLISTED
ISIN	INE044A01036
Name of company	Sun Pharmaceutical Industries Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	22-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	12-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	22-May-2025   10:40:00
End date and time of board meeting	22-May-2025   15:55:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-03-31
Indicate Company website link for updated RPT policy of the Company	https://sunpharma.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
The Company does not have any loans or borrowings. Hence there is no default.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	71857400000	230033300000
	Other income	1320000000	3694300000
	Total income	73177400000	233727600000
2	Expenses
(a)	Cost of materials consumed	13297000000	46906700000
(b)	Purchases of stock-in-trade	3257000000	13595300000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-20700000	-691700000
(d)	Employee benefit expense	6489100000	26082600000
(e)	Finance costs	2174200000	8932100000
(f)	Depreciation, depletion and amortisation expense	2919600000	12382700000
(f)	Other Expenses
1	Other expenses	21258500000	78759600000
2	Net (gain) / loss on foreign currency transactions	-2318100000	-2545400000
	Total other expenses	18940400000	76214200000
	Total expenses	47056600000	183421900000
3	Total profit before exceptional items and tax	26120800000	50305700000
4	Exceptional items	0	0
5	Total profit before tax	26120800000	50305700000
6	Tax expense
7	Current tax	4666800000	9086200000
8	Deferred tax	1449400000	-1606700000
9	Total tax expenses	6116200000	7479500000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	20004600000	42826200000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	20004600000	42826200000
17	Other comprehensive income net of taxes	270600000	-232000000
18	Total Comprehensive Income for the period	20275200000	42594200000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	2399300000	2399300000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		240999200000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	8.3	17.8
	Diluted earnings (loss) per share from continuing operations	8.3	17.8
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	8.3	17.8
	Diluted earnings (loss) per share from continuing and discontinued operations	8.3	17.8
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	43450500000
	Capital work-in-progress	5633900000
	Investment property	0
	Goodwill	1208000000
	Other intangible assets	25226700000
	Intangible assets under development	3758400000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	124101100000
	Trade receivables, non-current	0
	Loans, non-current	26633600000
	Other non-current financial assets	603100000
	Total non-current financial assets	151337800000
	Deferred tax assets (net)	11676400000
	Other non-current assets	2918900000
	Total non-current assets	245210600000
2	Current assets
	Inventories	37874900000
	Current financial asset
	Current investments	0
	Trade receivables, current	117014300000
	Cash and cash equivalents	4920200000
	Bank balance other than cash and cash equivalents	4184800000
	Loans, current	8687900000
	Other current financial assets	4097500000
	Total current financial assets	138904700000
	Current tax assets (net)	0
	Other current assets	10440200000
	Total current assets	187219800000
3	Non-current assets classified as held for sale	304100000
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	432734500000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	2399300000
	Other equity	240999200000
	Total equity attributable to owners of parent	243398500000
	Non controlling interest
	Total equity	243398500000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	1668500000
	Total non-current financial liabilities	1668500000
	Provisions, non-current	2414800000
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	0
	Other non-current liabilities	3767400000
	Total non-current liabilities	7850700000
	Current liabilities
	Current financial liabilities
	Borrowings, current	109544700000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	785600000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	33553800000
	Total Trade payable	34339400000
	Other current financial liabilities	24803900000
	Total current financial liabilities	168688000000
	Other current liabilities	5558000000
	Provisions, current	5024000000
	Current tax liabilities (Net)	2215300000
	Deferred government grants, Current	0
	Total current liabilities	181485300000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	189336000000
	Total equity and liabilites	432734500000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to profit or loss	-228400000	-176400000
	Total Amount of items that will not be reclassified to profit and loss	-228400000	-176400000
2	Income tax relating to items that will not be reclassified to profit or loss	-79800000	-61600000
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to profit and loss	644500000	-180100000
	Total Amount of items that will be reclassified to profit and loss	644500000	-180100000
4	Income tax relating to items that will be reclassified to profit or loss	225300000	-62900000
5	Total Other comprehensive income	270600000	-232000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			50305700000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			8932100000
	Adjustments for decrease (increase) in inventories			-3638700000
	Adjustments for decrease (increase) in trade receivables, current			-27151400000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			1007800000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			8011600000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-1008300000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			12382700000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			370100000
	Adjustments for provisions, current			-1031700000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-3915900000
	Adjustments for dividend income			0
	Adjustments for interest income			3210300000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-25900000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			2313000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-6964900000
	Net cash flows from (used in) operations			43340800000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			1353100000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			41987700000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			568200000
	Purchase of property, plant and equipment			7105100000
	Proceeds from sales of investment property			6345500000
	Purchase of investment property			6444700000
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			299100000
	Cash receipts from repayment of advances and loans made to other parties			6330300000
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			2539200000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-4029900000
	Net cash flows from (used in) investing activities	-2095600000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			118586200000
	Repayments of borrowings			119507600000
	Payments of lease liabilities			302900000
	Dividends paid			36139700000
	Interest paid			947800000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-38311800000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			1580300000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			75300000
	Net increase (decrease) in cash and cash equivalents			1655600000
	Cash and cash equivalents cash flow statement at beginning of period			3264600000
	Cash and cash equivalents cash flow statement at end of period			4920200000